Literature DB >> 17135585

Financial relationships between institutional review board members and industry.

Eric G Campbell1, Joel S Weissman, Christine Vogeli, Brian R Clarridge, Melissa Abraham, Jessica E Marder, Greg Koski.   

Abstract

BACKGROUND: Little is known about the nature, extent, and consequences of financial relationships between industry and institutional review board (IRB) members in academic institutions. We surveyed IRB members about such relationships.
METHODS: We surveyed a random sample of 893 IRB members at 100 academic institutions (response rate, 67.2%). The questionnaire focused on the financial relationships that the members had with industry (e.g., employment, membership on boards, consulting, receipt of royalties, and paid speaking).
RESULTS: We found that 36% of IRB members had had at least one relationship with industry in the past year. Of the respondents, 85.5% said they never thought that the relationships that another IRB member had with industry affected his or her IRB-related decisions in an inappropriate way, 11.9% said they thought this occurred rarely, 2.4% thought it occurred sometimes, and 0.2% thought it occurred often. Seventy-eight respondents (15.1%) reported that at least one protocol came before their IRB during the previous year that was sponsored either by a company with which they had a relationship or by a competitor of that company, both of which could be considered conflicts of interest. Of these 78 members (62 voting members and 16 nonvoting members), 57.7% reported that they always disclosed the relationship to an IRB official, 7.7% said they sometimes did, 11.5% said they rarely did, and 23.1% said they never did. Of the 62 voting members who reported conflicts, 64.5% reported that they never voted on the protocol, 4.8% said they rarely did, 11.3% said they sometimes did, and 19.4% said they always did. Most respondents reported that the views of IRB members who had experience working with industry were beneficial in reviewing industry-sponsored protocols.
CONCLUSIONS: Relationships between IRB members and industry are common, and members sometimes participate in decisions about protocols sponsored by companies with which they have a financial relationship. Current regulations and policies should be examined to be sure that there is an appropriate way to handle conflicts of interest stemming from relationships with industry. Copyright 2006 Massachusetts Medical Society.

Mesh:

Year:  2006        PMID: 17135585     DOI: 10.1056/NEJMsa061457

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  26 in total

1.  Towards a balanced approach to identifying conflicts of interest faced by institutional review boards.

Authors:  Sharon Kaur; Sujata Balan
Journal:  Theor Med Bioeth       Date:  2015-10

2.  Health for all? Dream on!

Authors:  Bassem Saab
Journal:  Br J Gen Pract       Date:  2009-01       Impact factor: 5.386

3.  Applying research ethics guidelines: the view from a sub-saharan research ethics committee.

Authors:  Gail E Henderson; Amy L Corneli; David B Mahoney; Daniel K Nelson; Charles Mwansambo
Journal:  J Empir Res Hum Res Ethics       Date:  2007-06       Impact factor: 1.742

4.  Correlation between financial relationships with commercial interests and research prominence at an oncology meeting.

Authors:  Beverly Moy; Angela R Bradbury; Paul R Helft; Brian L Egleston; Moktar Sheikh-Salah; Jeffrey Peppercorn
Journal:  J Clin Oncol       Date:  2013-06-17       Impact factor: 44.544

5.  Institutional review board community members: who are they, what do they do, and whom do they represent?

Authors:  Robert Klitzman
Journal:  Acad Med       Date:  2012-07       Impact factor: 6.893

6.  Key personnel and "long distance" settings: determining who must report financial conflict of interest.

Authors:  John Lynch; Christopher J Lindsell
Journal:  Account Res       Date:  2010-07       Impact factor: 2.622

7.  Ethics and technology transfer: patients, patents, and public trust.

Authors:  Deborah Zucker
Journal:  J Investig Med       Date:  2011-06       Impact factor: 2.895

8.  Are central institutional review boards the solution? The National Heart, Lung, and Blood Institute Working Group's report on optimizing the IRB process.

Authors:  Alice M Mascette; Gordon R Bernard; Donna Dimichele; Jesse A Goldner; Robert Harrington; Paul A Harris; Hilary S Leeds; Thomas A Pearson; Bonnie Ramsey; Todd H Wagner
Journal:  Acad Med       Date:  2012-12       Impact factor: 6.893

9.  How are the interests of incapacitated research participants protected through legislation? An Italian study on legal agency for dementia patients.

Authors:  Sabina Gainotti; Susanna Fusari Imperatori; Stefania Spila-Alegiani; Laura Maggiore; Francesca Galeotti; Nicola Vanacore; Carlo Petrini; Roberto Raschetti; Claudio Mariani; Francesca Clerici
Journal:  PLoS One       Date:  2010-06-16       Impact factor: 3.240

10.  Institutional review board challenges related to community-based participatory research on human exposure to environmental toxins: a case study.

Authors:  Phil Brown; Rachel Morello-Frosch; J G Brody; Rebecca Gasior Altman; Ruthann A Rudel; Laura Senier; Carla Pérez; Ruth Simpson
Journal:  Environ Health       Date:  2010-07-16       Impact factor: 5.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.